Literature DB >> 35972953

Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.

Friedemann Schad, Anja Thronicke, Megan L Steele, Antje Merkle, Burkhard Matthes, Christian Grah, Harald Matthes.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0203058.].

Entities:  

Year:  2022        PMID: 35972953      PMCID: PMC9380908          DOI: 10.1371/journal.pone.0273387

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


The following information is missing from the Competing Interests statement: Dr. Harald Matthes is a member of the board of directors at Weleda AG, a company that until 2016 distributed Iscador, a mistletoe preparation. In addition, Dr. Harald Matthes is a member of the board of the Hufelandgesellschaft e. V. in Germany; President of the DAHN (German Academy for Homeopathy and Naturopathy); and medical director and managing director of Gemeinschaftskrankenhaus Havelhöhe, a hospital for anthroposophic medicine. Dr. Harald Matthes is also a recipient on an endowed professorship from Charité in Berlin on Integrative and Anthroposophical Medicine. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
  1 in total

1.  Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.

Authors:  Friedemann Schad; Anja Thronicke; Megan L Steele; Antje Merkle; Burkhard Matthes; Christian Grah; Harald Matthes
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.